Lipitor's Primary Protein Target
Lipitor (atorvastatin) mainly interacts with HMG-CoA reductase, the enzyme that limits the rate of cholesterol synthesis in the liver. By competitively binding to its active site, Lipitor inhibits this protein, reducing mevalonate production and lowering LDL cholesterol levels.[1]
How the Interaction Works
HMG-CoA reductase converts HMG-CoA to mevalonic acid using NADPH. Lipitor mimics HMG-CoA's structure, binding with high affinity (often in its active hydroxyl acid form after metabolism). This blocks the enzyme's catalytic site, cutting cholesterol biosynthesis by up to 50% at therapeutic doses.[1][2]
Why HMG-CoA Reductase Matters for Statins
All statins target HMG-CoA reductase, but Lipitor's design gives it potent, long-lasting inhibition compared to older ones like lovastatin. This selectivity reduces off-target effects while effectively treating hypercholesterolemia.[2]
Other Proteins Lipitor Touches
Lipitor weakly interacts with proteins like cytochrome P450 enzymes (CYP3A4 for metabolism) and transporters (e.g., OATP1B1 for uptake), which affect dosing and drug interactions. But HMG-CoA reductase remains the key therapeutic target.[1]
[1]: DrugPatentWatch.com - Atorvastatin
[2]: PubMed - Mechanism of atorvastatin